Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Wason

Showing results (11-20 of 94) with videos related to

Pageof 10
Sort By:
Pharmaceutical Statistics|December 22, 2017
Response-adaptive designs for binary responses: How to offer patient benefit while being robust to time trends?Sofía S Villar, Jack Bowden, James Wason
Statistical Science : a Review Journal of the Institute of Mathematical Statistics|May 10, 2016
Multi-armed Bandit Models for the Optimal Design of Clinical Trials: Benefits and ChallengesSofía S Villar, Jack Bowden, James Wason
BMJ Open Ophthalmology|July 6, 2019
Anti-VEGF intervention in neovascular AMD: benefits and risks restated as natural frequenciesLouis Clearkin, Balasubramanian Ramasamy, James Wason, et al.
Annals of Neurology|February 27, 2010
What role for genetics in the prediction of multiple sclerosis?Stephen Sawcer, Maria Ban, James Wason, et al.
Statistical Methods in Medical Research|December 18, 2012
Some recommendations for multi-arm multi-stage trialsJames Wason, Dominic Magirr, Martin Law, et al.
Emergency Medicine Journal : EMJ|November 27, 2020
Oxygen therapy and inpatient mortality in COPD exacerbationCarlos Echevarria, John Steer, James Wason, et al.
Statistical Methods in Medical Research|September 18, 2014
A multi-stage drop-the-losers design for multi-arm clinical trialsJames Wason, Nigel Stallard, Jack Bowden, et al.
Pharmaceutical Statistics|September 8, 2021
A two-stage drop-the-losers design for time-to-event outcome using a historical control armRachid Abbas, James Wason, Stefan Michiels, et al.
BMC Geriatrics|March 28, 2020
Developing a composite outcome measure for frailty prevention trials - rationale, derivation and sample size comparison with other candidate measuresMiles D Witham, James Wason, Richard Dodds, et al.
Pharmaceutical Statistics|March 24, 2021
Treatment allocation strategies for umbrella trials in the presence of multiple biomarkers: A comparison of methodsLuke Ondijo Ouma, Michael J Grayling, Haiyan Zheng, et al.
Pageof 10

Showing results (11-20 of 94) with videos related to

Sort By:
Pageof 10
Pharmaceutical Statistics|December 22, 2017
Response-adaptive designs for binary responses: How to offer patient benefit while being robust to time trends?Sofía S Villar, Jack Bowden, James Wason
Statistical Science : a Review Journal of the Institute of Mathematical Statistics|May 10, 2016
Multi-armed Bandit Models for the Optimal Design of Clinical Trials: Benefits and ChallengesSofía S Villar, Jack Bowden, James Wason
BMJ Open Ophthalmology|July 6, 2019
Anti-VEGF intervention in neovascular AMD: benefits and risks restated as natural frequenciesLouis Clearkin, Balasubramanian Ramasamy, James Wason, et al.
Annals of Neurology|February 27, 2010
What role for genetics in the prediction of multiple sclerosis?Stephen Sawcer, Maria Ban, James Wason, et al.
Statistical Methods in Medical Research|December 18, 2012
Some recommendations for multi-arm multi-stage trialsJames Wason, Dominic Magirr, Martin Law, et al.
Emergency Medicine Journal : EMJ|November 27, 2020
Oxygen therapy and inpatient mortality in COPD exacerbationCarlos Echevarria, John Steer, James Wason, et al.
Statistical Methods in Medical Research|September 18, 2014
A multi-stage drop-the-losers design for multi-arm clinical trialsJames Wason, Nigel Stallard, Jack Bowden, et al.
Pharmaceutical Statistics|September 8, 2021
A two-stage drop-the-losers design for time-to-event outcome using a historical control armRachid Abbas, James Wason, Stefan Michiels, et al.
BMC Geriatrics|March 28, 2020
Developing a composite outcome measure for frailty prevention trials - rationale, derivation and sample size comparison with other candidate measuresMiles D Witham, James Wason, Richard Dodds, et al.
Pharmaceutical Statistics|March 24, 2021
Treatment allocation strategies for umbrella trials in the presence of multiple biomarkers: A comparison of methodsLuke Ondijo Ouma, Michael J Grayling, Haiyan Zheng, et al.
Pageof 10